Gregory J Riely

Gregory J Riely

UNVERIFIED PROFILE

Are you Gregory J Riely?   Register this Author

Register author
Gregory J Riely

Gregory J Riely

Publications by authors named "Gregory J Riely"

Are you Gregory J Riely?   Register this Author

100Publications

4328Reads

31Profile Views

Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.

J Thorac Oncol 2019 Oct 19;14(10):1784-1793. Epub 2019 Jun 19.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New York. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.06.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764905PMC
October 2019

Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.

JAMA 2019 08;322(8):764-774

Thoracic Oncology Service, Division of Solid Tumor, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2019.11058DOI Listing
August 2019

Lessons learned from routine, targeted assessment of liquid biopsies for T790M resistance mutation in patients with mutant lung cancers.

Acta Oncol 2019 Jul 26:1-6. Epub 2019 Jul 26.

b Diagnostic Molecular Pathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center , New York , NY , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2019.1645354DOI Listing
July 2019

Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.

J Thorac Oncol 2019 May 1;14(5):802-815. Epub 2019 Mar 1.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.12.038DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486868PMC
May 2019

Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with -Mutant Lung Cancers.

Clin Cancer Res 2019 Feb 25;25(3):1063-1069. Epub 2018 Jul 25.

Department of Medicine, Division of Solid Tumor Oncology, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-1102DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347551PMC
February 2019

Type A thymoma presenting with bone metastasis.

Histopathology 2018 10 8;73(4):701-703. Epub 2018 Jul 8.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/his.13662
Publisher Site
http://dx.doi.org/10.1111/his.13662DOI Listing
October 2018

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.

J Clin Oncol 2018 10 20;36(28):2872-2878. Epub 2018 Aug 20.

Matthew D. Hellmann, Parker Institute for Cancer Immunotherapy; Kathryn C. Arbour, Niamh Long, Hira Rizvi, Andy Ni, W. Victoria Lai, Joshua K. Sabari, Andrew J. Plodkowski, Darragh Halpenny, Jamie E. Chaft, Gregory J. Riely, and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center; Kathryn C. Arbour, W. Victoria Lai, Joshua K. Sabari, Jamie E. Chaft, Gregory J. Riely, and Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Laura Mezquita, Roberto Ferrara, Lizza E.L. Hendriks, Caroline Caramella, Benjamin Besse, and David Planchard, Gustave Roussy Cancer Center, Villejuif; Edouard Auclin, Hôpital Européen Georges Pompidou; Benjamin Besse, Paris-Sud University, Le Kremlin Bicêtre, Paris, France; Gala Martínez-Bernal, Virgen del Rocío Hospital, Seville, Spain; Lizza E.L. Hendriks, Maastricht University Medical Center, Maastricht, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.79.0006DOI Listing
October 2018

Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.

J Clin Oncol 2018 08 10;36(24):2532-2537. Epub 2018 Jul 10.

Bob T. Li, Ronglai Shen, Darren Buonocore, Zachary T. Olah, Ai Ni, Michelle S. Ginsberg, Gary A. Ulaner, Michael Offin, Daniel Feldman, Helen H. Won, Edyta B. Brzostowski, Gregory J. Riely, David B. Solit, David M. Hyman, Alexander Drilon, Charles M. Rudin, Michael F. Berger, Jose Baselga, Maurizio Scaltriti, Maria E. Arcila, and Mark G. Kris, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York, NY; Bob T. Li, Nick Pavlakis, and Stephen Clarke, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia; and Todd Hembrough, Fabiola Cecchi, and Sarit Schwartz, NantOmics, Rockville, MD.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2018.77.9777
Publisher Site
http://dx.doi.org/10.1200/JCO.2018.77.9777DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366814PMC
August 2018

Improving therapy for patients with epidermal growth factor receptor-mutant lung cancer.

Cancer 2018 06 12;124(11):2272-2275. Epub 2018 Apr 12.

Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31289DOI Listing
June 2018

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

J Clin Oncol 2018 03 16;36(7):633-641. Epub 2018 Jan 16.

Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson, Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub, Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila, Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A. Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.3384DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075848PMC
March 2018

Case for Stopping Targeted Therapy When Lung Cancer Progresses on Treatment in Hospice-Eligible Patients.

J Oncol Pract 2017 12 5;13(12):780-783. Epub 2017 Oct 5.

Johns Hopkins, Baltimore, MD; Indiana University, Bloomington, IN; UT Southwestern Medical School, Dallas, TX; Virginia Commonwealth University Massey Cancer Center, Richmond; Inova Schar Cancer Institute, Falls Church; ASCO, Alexandria, VA; Einstein Medical Center, Philadelphia, PA; Juravinski Cancer Centre, Hamilton; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Lombardi Cancer Center, Washington, DC; Lahey Hospital & Medical Center, Burlington, MA; William Beaumont Hospital, Royal Oak; University of Michigan, Ann Arbor, MI; Memorial Sloan Kettering Cancer Center, New York, NY; Circle of Hope for Cancer Research, St Cloud, FL; and Helen F. Graham Cancer Center, Newark, DE.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2017.027367DOI Listing
December 2017

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

J Clin Oncol 2017 Oct 14;35(30):3484-3515. Epub 2017 Aug 14.

Nasser Hanna, Indiana University Simon Cancer Center, Indianapolis, IN; David Johnson, University of Texas Southwestern Medical Center, Dallas, TX; Sarah Temin, American Society of Clinical Oncology, Alexandria; Sherman Baker Jr, Virginia Commonwealth University Health System Massey Cancer Center, Richmond; Joan H. Schiller, Inova Schar Cancer Institute, Fairfax, VA; Julie Brahmer and Thomas J. Smith, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Peter M. Ellis, Juravinski Cancer Centre, Hamilton; Natasha B. Leighl, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Giuseppe Giaccone, Georgetown University, Washington, DC; Paul J. Hesketh, Lahey Hospital and Medical Center, Burlington, MA; Ishmael Jaiyesimi, William Beaumont Hospital, Royal Oak; Bryan J. Schneider, University of Michigan Health System, Ann Arbor, MI; Gregory J. Riely, Memorial Sloan-Kettering Cancer Center, New York, NY; Joan Tashbar, Circle of Hope for Cancer Research, Orlando, FL; William A. Biermann, Einstein Medical Center Montgomery, East Norriton, PA; and Gregory Masters, Helen F. Graham Cancer Center and Research Institute, Newark, DE.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.6065DOI Listing
October 2017

Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.

PLoS One 2017 3;12(8):e0182665. Epub 2017 Aug 3.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0182665PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542609PMC
August 2017

Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

Authors:
Ahmet Zehir Ryma Benayed Ronak H Shah Aijazuddin Syed Sumit Middha Hyunjae R Kim Preethi Srinivasan Jianjiong Gao Debyani Chakravarty Sean M Devlin Matthew D Hellmann David A Barron Alison M Schram Meera Hameed Snjezana Dogan Dara S Ross Jaclyn F Hechtman Deborah F DeLair JinJuan Yao Diana L Mandelker Donavan T Cheng Raghu Chandramohan Abhinita S Mohanty Ryan N Ptashkin Gowtham Jayakumaran Meera Prasad Mustafa H Syed Anoop Balakrishnan Rema Zhen Y Liu Khedoudja Nafa Laetitia Borsu Justyna Sadowska Jacklyn Casanova Ruben Bacares Iwona J Kiecka Anna Razumova Julie B Son Lisa Stewart Tessara Baldi Kerry A Mullaney Hikmat Al-Ahmadie Efsevia Vakiani Adam A Abeshouse Alexander V Penson Philip Jonsson Niedzica Camacho Matthew T Chang Helen H Won Benjamin E Gross Ritika Kundra Zachary J Heins Hsiao-Wei Chen Sarah Phillips Hongxin Zhang Jiaojiao Wang Angelica Ochoa Jonathan Wills Michael Eubank Stacy B Thomas Stuart M Gardos Dalicia N Reales Jesse Galle Robert Durany Roy Cambria Wassim Abida Andrea Cercek Darren R Feldman Mrinal M Gounder A Ari Hakimi James J Harding Gopa Iyer Yelena Y Janjigian Emmet J Jordan Ciara M Kelly Maeve A Lowery Luc G T Morris Antonio M Omuro Nitya Raj Pedram Razavi Alexander N Shoushtari Neerav Shukla Tara E Soumerai Anna M Varghese Rona Yaeger Jonathan Coleman Bernard Bochner Gregory J Riely Leonard B Saltz Howard I Scher Paul J Sabbatini Mark E Robson David S Klimstra Barry S Taylor Jose Baselga Nikolaus Schultz David M Hyman Maria E Arcila David B Solit Marc Ladanyi Michael F Berger

Nat Med 2017 08;23(8):1004

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm0817-1004cDOI Listing
August 2017

OncoKB: A Precision Oncology Knowledge Base.

JCO Precis Oncol 2017 Jul 16;2017. Epub 2017 May 16.

, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Gynecologic Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Breast Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Breast Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Head and Neck Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , , Department of Hematology and Oncology, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA, 92675, USA; , Department of R&D and Bioinformatics, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA, 92675, USA; , Head and Neck Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Gynecologic Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Sarcoma Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Sarcoma Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Oncology and Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA , Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Breast Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
https://www.researchgate.net/profile/Debyani_Chakravarty/pub
Web Search
http://ascopubs.org/doi/10.1200/PO.17.00011
Publisher Site
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586540PMC
http://dx.doi.org/10.1200/PO.17.00011DOI Listing
July 2017

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

Authors:
Ahmet Zehir Ryma Benayed Ronak H Shah Aijazuddin Syed Sumit Middha Hyunjae R Kim Preethi Srinivasan Jianjiong Gao Debyani Chakravarty Sean M Devlin Matthew D Hellmann David A Barron Alison M Schram Meera Hameed Snjezana Dogan Dara S Ross Jaclyn F Hechtman Deborah F DeLair JinJuan Yao Diana L Mandelker Donavan T Cheng Raghu Chandramohan Abhinita S Mohanty Ryan N Ptashkin Gowtham Jayakumaran Meera Prasad Mustafa H Syed Anoop Balakrishnan Rema Zhen Y Liu Khedoudja Nafa Laetitia Borsu Justyna Sadowska Jacklyn Casanova Ruben Bacares Iwona J Kiecka Anna Razumova Julie B Son Lisa Stewart Tessara Baldi Kerry A Mullaney Hikmat Al-Ahmadie Efsevia Vakiani Adam A Abeshouse Alexander V Penson Philip Jonsson Niedzica Camacho Matthew T Chang Helen H Won Benjamin E Gross Ritika Kundra Zachary J Heins Hsiao-Wei Chen Sarah Phillips Hongxin Zhang Jiaojiao Wang Angelica Ochoa Jonathan Wills Michael Eubank Stacy B Thomas Stuart M Gardos Dalicia N Reales Jesse Galle Robert Durany Roy Cambria Wassim Abida Andrea Cercek Darren R Feldman Mrinal M Gounder A Ari Hakimi James J Harding Gopa Iyer Yelena Y Janjigian Emmet J Jordan Ciara M Kelly Maeve A Lowery Luc G T Morris Antonio M Omuro Nitya Raj Pedram Razavi Alexander N Shoushtari Neerav Shukla Tara E Soumerai Anna M Varghese Rona Yaeger Jonathan Coleman Bernard Bochner Gregory J Riely Leonard B Saltz Howard I Scher Paul J Sabbatini Mark E Robson David S Klimstra Barry S Taylor Jose Baselga Nikolaus Schultz David M Hyman Maria E Arcila David B Solit Marc Ladanyi Michael F Berger

Nat Med 2017 Jun 8;23(6):703-713. Epub 2017 May 8.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/doifinder/10.1038/nm.4333
Publisher Site
http://dx.doi.org/10.1038/nm.4333DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461196PMC
June 2017

Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib.

Lung Cancer 2017 06 24;108:109-114. Epub 2017 Mar 24.

Departments of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.03.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477661PMC
June 2017

Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.

Hematol Oncol Clin North Am 2017 02;31(1):101-111

Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2016.08.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5154547PMC
February 2017

Targeting ALK: Precision Medicine Takes on Drug Resistance.

Cancer Discov 2017 02 25;7(2):137-155. Epub 2017 Jan 25.

Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-16-1123DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5296241PMC
February 2017

A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR-Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib.

J Thorac Oncol 2017 01 6;12(1):102-109. Epub 2016 Sep 6.

Breast Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.08.140DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5552054PMC
January 2017

Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency.

J Clin Oncol 2017 01 28;35(3):271-273. Epub 2016 Nov 28.

Kristen M. Cunanan, Mithat Gonen, Ronglai Shen, David M. Hyman, Gregory J. Riely, Colin B. Begg, and Alexia Iasonos, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.9751DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559900PMC
January 2017

Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes.

Clin Lung Cancer 2016 09 21;17(5):e121-e129. Epub 2016 Jan 21.

Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2016.01.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474315PMC
September 2016

NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.

J Natl Compr Canc Netw 2016 07;14(7):825-36

From The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; Huntsman Cancer Institute at the University of Utah; UC San Diego Moores Cancer Center; Fox Chase Cancer Center; University of Colorado Cancer Center; Roswell Park Cancer Institute; Dana-Farber/Brigham and Women's Cancer Center; Duke Cancer Institute; Moffitt Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; Vanderbilt-Ingram Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; The University of Texas MD Anderson Cancer Center; Fred & Pamela Buffett Cancer Center; Massachusetts General Hospital Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; University of Michigan Comprehensive Cancer Center; Stanford Cancer Institute; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; City of Hope Comprehensive Cancer Center; Memorial Sloan Kettering Cancer Center; Mayo Clinic Cancer Center; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; and National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2016.0087DOI Listing
July 2016

Beyond "second-line" in non-small cell lung cancer: therapy and supportive care.

Am Soc Clin Oncol Educ Book 2015 :e414-8

From Seattle Cancer Care Alliance, University of Washington, Seattle, WA; US Oncology Research, Ocala, FL; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2015.35.e414DOI Listing
February 2016

Should EGFR tyrosine kinase inhibitors be used in non-small cell lung cancer in the absence of EGFR mutations? No, EGFR TKIs should be reserved for patients with EGFR mutations.

Authors:
Gregory J Riely

Clin Adv Hematol Oncol 2016 Jan;14(1):41, 44-5

Weill Cornell Medical College and Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
January 2016

Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.

JAMA Oncol 2015 Oct;1(7):982-4

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York4Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.1066DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4665629PMC
October 2015

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.

J Clin Oncol 2015 Jun 26;33(17):1881-8. Epub 2015 Jan 26.

Daniel B. Costa, Beth Israel Deaconess Medical Center, Harvard Medical School; Alice T. Shaw, Massachusetts General Hospital, Harvard Medical School, Boston, MA; Sai-Hong I. Ou, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Irvine; S. Martin Shreeve, Paulina Selaru, and Keith D. Wilner, Pfizer Oncology, La Jolla, CA; Benjamin J. Solomon, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Gregory J. Riely, Memorial Sloan-Kettering Cancer Center; Patrick Schnell, Pfizer Oncology, New York, NY; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea; Caicun Zhou, Shanghai Pulmonary Hospital, Shanghai, People's Republic of China; Anna Polli, Pfizer Oncology, Milan; Lucio Crinò, Perugia University Medical School, Perugia, Italy; Robin Wiltshire, Pfizer Oncology, Tadworth, United Kingdom; and D. Ross Camidge, University of Colorado Denver, Aurora, CO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.0539DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451171PMC
June 2015

Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.

Cancer 2015 Jun 17;121(12):2078-82. Epub 2015 Mar 17.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29313DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4783794PMC
June 2015

Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

J Clin Oncol 2015 May 13;33(15):1666-73. Epub 2015 Apr 13.

Melissa L. Johnson, Jyoti D. Patel, Eric M. Hart, Bing Bing Weitner, and Alfred W. Rademaker, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; and Helena A. Yu, Mark G. Kris, and Gregory J. Riely, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/04/13/JCO.2014.59
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.59.7328
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.59.7328DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881377PMC
May 2015

Non-Small Cell Lung Cancer, Version 6.2015.

J Natl Compr Canc Netw 2015 May;13(5):515-24

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University of Washington/Seattle Cancer Care Alliance; Huntsman Cancer Institute at the University of Utah; UC San Diego Moores Cancer Center; Fox Chase Cancer Center; University of Colorado Cancer Center; Roswell Park Cancer Institute; Dana-Farber/Brigham and Women's Cancer Center; Duke Cancer Institute; Moffitt Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; City of Hope Comprehensive Cancer Center; Vanderbilt-Ingram Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; The University of Texas MD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Fred & Pamela Buffett Cancer Center; Massachusetts General Hospital Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; University of Michigan Comprehensive Cancer Center; Stanford Cancer Institute; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Mayo Clinic Cancer Center; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; and National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2015.0071DOI Listing
May 2015

EGFR: The Paradigm of an Oncogene-Driven Lung Cancer.

Clin Cancer Res 2015 May;21(10):2221-6

Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-3154DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435716PMC
May 2015

Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas.

J Thorac Oncol 2015 Mar;10(3):431-7

*Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, †Department of Epidemiology and Biostatistics, ‡Department of Pathology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY; §Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA; ‖Department of Medicine, Vanderbilt Ingram Cancer Center, Franklin, TN; and ¶Lowe center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000432DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479120PMC
March 2015

Massively parallel sequencing identifies recurrent mutations in TP53 in thymic carcinoma associated with poor prognosis.

J Thorac Oncol 2015 Feb;10(2):373-80

Departments of *Pathology, †Surgery, ‡Medicine, and §Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000397DOI Listing
February 2015

Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors.

Clin Cancer Res 2014 Dec 10;20(23):5898-907. Epub 2014 Oct 10.

Department of Medicine, Vanderbilt University School of Medicine and Vanderbilt Ingram Cancer Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-13-2437DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4253858PMC
December 2014

Clinical characteristics and outcomes for patients with thymic carcinoma: evaluation of Masaoka staging.

J Thorac Oncol 2014 Dec;9(12):1810-5

*Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, and Departments of †Epidemiology and Biostatistics, ‡Radiology, §Surgery, ‖Radiation Oncology, ¶Pathology, Memorial Sloan Kettering Cancer Center, New York, and Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000363DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4663074PMC
December 2014

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

N Engl J Med 2014 Nov 27;371(21):1963-71. Epub 2014 Sep 27.

From the Massachusetts General Hospital Cancer Center (A.T.S., L.P.L., Z.Z., J.W.C., A.J.I.), Dana-Farber Cancer Institute (G.I.S.), and Beth Israel Deaconess Medical Center (D.B.C.) - all in Boston; University of California at Irvine, Irvine (S.-H.I.O.), and Pfizer Oncology, La Jolla (W.T., S.M.S., L.M.T., J.G.C., K.D.W.) - both in California; Seoul National University Hospital, Seoul, South Korea (Y.-J.B.); University of Colorado, Aurora (D.R.C., M.V.-G., R.C.D.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.); University of Chicago, Chicago (R.S.); Memorial Sloan Kettering Cancer Center, New York (G.J.R.); Karolinska Institutet, Stockholm (Z.Z.); and Rho, Chapel Hill, NC (P.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1406766DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264527PMC
November 2014

Emerging science and therapies in non-small-cell lung cancer: targeting the MET pathway.

Clin Lung Cancer 2014 Nov;15(6):475

Assistant Attending, Memorial Sloan-Kettering Cancer Center, Assistant Professor, Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2014.08.001DOI Listing
November 2014

Are there imaging characteristics associated with lung adenocarcinomas harboring ALK rearrangements?

Lung Cancer 2014 Nov 17;86(2):190-4. Epub 2014 Sep 17.

Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2014.09.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4655968PMC
November 2014

Clinical characteristics and course of 63 patients with BRAF mutant lung cancers.

J Thorac Oncol 2014 Nov;9(11):1669-74

Departments of *Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, †Epidemiology and Biostatistics, and ‡Pathology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000344DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251710PMC
November 2014

Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation.

Am J Surg Pathol 2014 Aug;38(8):1118-27

*Department of Surgery, Division of Thoracic Service §Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology Departments of †Pathology ∥Epidemiology and Biostatistics ¶Center for Cell Engineering, Memorial Sloan-Kettering Cancer Center, New York, NY ‡Faculty of Medicine, Department of Diagnostic Pathology, Kagawa University, Kagawa, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000000246DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4666292PMC
August 2014

Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma.

Int J Radiat Oncol Biol Phys 2014 Jun 25;89(2):322-9. Epub 2014 Mar 25.

Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2014.02.022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5691362PMC
June 2014

Small-cell lung cancers in patients who never smoked cigarettes.

J Thorac Oncol 2014 Jun;9(6):892-6

*Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center; †Department of Medicine, Weill Cornell Medical College; ‡Department of Pathology; and §Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000142DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199745PMC
June 2014

Can IASLC/ATS/ERS subtype help predict response to chemotherapy in small biopsies of advanced lung adenocarcinoma?

Eur Respir J 2014 May;43(5):1240-2

Dept of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1183/09031936.00048814DOI Listing
May 2014

Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease.

Am J Surg Pathol 2014 Apr;38(4):448-60

*Department of Surgery, Division of Thoracic Service †Department of Pathology ¶Department of Epidemiology & Biostatistics #Department of Medicine, Division of Solid Tumor Oncology, Thoracic Oncology Service **Center for Cell Engineering, Memorial Sloan-Kettering Cancer Center, New York, NY ‡Department of Diagnostic Pathology, Faculty of Medicine, Kagawa University, Kagawa §Department of Laboratory Medicine, Shinshu University Hospital, Matsumoto ∥Department of Diagnostic Pathology, the Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000000134DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164170PMC
April 2014

Germline EGFR T790M mutation found in multiple members of a familial cohort.

J Thorac Oncol 2014 Apr;9(4):554-8

*Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine; †Department of Pathology, ‡Clinical Genetics Service, Department of Medicine, §Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York; and ‖Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000052DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412273PMC
April 2014

Failure patterns relative to radiation treatment fields for stage II-IV thymoma.

J Thorac Oncol 2014 Mar;9(3):403-9

Departments of *Radiation Oncology, †Thoracic Surgery, ‡Thoracic Oncology, §Pathology, ¶Epidemiology and Biostatistics, and ‖Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York; Departments of #Radiation Oncology and **Thoracic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas; and ††Department of Radiation Oncology, Mt. Sinai Medical Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000099DOI Listing
March 2014

Ceritinib in ALK-rearranged non-small-cell lung cancer.

N Engl J Med 2014 Mar;370(13):1189-97

From Massachusetts General Hospital, Boston (A.T.S., J.A.E.); Seoul National University Hospital, Seoul, South Korea (D.-W.K.); Fox Chase Cancer Center, Philadelphia (R.M.); National Cancer Center and Genome Institute of Singapore, Singapore (D.S.W.T.); Vall d'Hebron University, Barcelona (E.F.); University of Washington, Seattle (L.Q.M.C.); University of Colorado, Denver (D.R.C.); University Hospital KU Leuven, Leuven, Belgium (J.V.); Huntsman Cancer Institute, Salt Lake City (S.S.); Istituto Europeo di Oncologia (T.D.P.) and Istituto di Ricovero e Cura a Carattere Scientifico Istituto Clinico Humanitas (A.S.) - both in Milan; Memorial Sloan-Kettering Cancer Center, New York (G.J.R.); Peter MacCallum Cancer Center, Melbourne, VIC, Australia (B.J.S.); Center for Integrated Oncology, University Hospital Cologne, Cologne (J.W.), Thoraxklinik, University of Heidelberg, Translational Lung Research Center Heidelberg, German Center for Lung Research (M.T.), and German Cancer Consortium (M.S.), Heidelberg, and University Duisburg-Essen, Essen (M.S.) - all in Germany; Princess Margaret Cancer Center, Toronto (G.L.); and Novartis Institutes for BioMedical Research, Cambridge, MA (Y.Y.L., M.G., A.L.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1311107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4079055PMC
March 2014

[Chemotherapy definitions and policies for thymic malignancies].

Zhongguo Fei Ai Za Zhi 2014 Feb;17(2):116-21

Division of Hematology and Oncology, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana.

View Article

Download full-text PDF

Source
http://www.lungca.org/index.php?journal=01&page=article&
Publisher Site
http://dx.doi.org/10.3779/j.issn.1009-3419.2014.02.09DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131237PMC
February 2014

Unsuspected collision of synchronous lung adenocarcinomas: a potential cause of aberrant driver mutation profiles.

J Thorac Oncol 2014 Jan;9(1):e1-3

*Department of Pathology, †Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York; ‡Computational Biology Program, Sloan-Kettering Institute, New York, New York; and §Department of Medicine Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3182a471c3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868006PMC
January 2014

KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma.

Mod Pathol 2013 Oct 26;26(10):1307-19. Epub 2013 Apr 26.

Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.2013.74DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3732528PMC
October 2013

Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab.

Cancer Chemother Pharmacol 2013 Aug 28;72(2):453-61. Epub 2013 Jun 28.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical School, 300 East 66th Street, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-013-2219-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4653739PMC
August 2013

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Clin Cancer Res 2013 Apr 7;19(8):2240-7. Epub 2013 Mar 7.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-2246DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3630270PMC
April 2013

New pathologic classification of lung cancer: relevance for clinical practice and clinical trials.

J Clin Oncol 2013 Mar 11;31(8):992-1001. Epub 2013 Feb 11.

Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.46.9270DOI Listing
March 2013

Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers.

J Natl Compr Canc Netw 2013 Feb;11(2):161-9

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3673302PMC
http://dx.doi.org/10.6004/jnccn.2013.0024DOI Listing
February 2013

Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers.

J Thorac Oncol 2013 Jan;8(1):123-5

Department of Medicine, Division of Solid Tumor Oncology, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e31827914eaDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3534987PMC
January 2013